Datasheet

CDIP Antibody
CATALOG NUMBER: 5047

Availability: In stock

$0.00
Product Price Options
$0.00
Specifications
Properties
Additional Info
Background

Specifications

SPECIES REACTIVITY:Human, Mouse
HOMOLOGY:Predicted species reactivity based on immunogen sequence: Bovine: (100%)
TESTED APPLICATIONS:ELISA, IF, IHC-P, WB
APPLICATIONS:CDIP antibody can be used for detection of CDIP by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
POSITIVE CONTROL:1) Cat. No. 1303 - Human Brain Tissue Lysate
IMMUNOGEN:CDIP antibody was raised against a 16 amino acid synthetic peptide near the center of human CDIP.

The immunogen is located within amino acids 40 - 90 of CDIP.
HOST SPECIES:Rabbit

Properties

PURIFICATION:CDIP Antibody is affinity chromatography purified via peptide column.
PHYSICAL STATE:Liquid
BUFFER:CDIP Antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:CDIP antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
CLONALITY:Polyclonal
ISOTYPE:IgG
CONJUGATE:Unconjugated

Additional Info

ALTERNATE NAMES:CDIP Antibody: I1, CDIP, LITAFL, C16orf5, Cell death-inducing p53-target protein 1, Cell death involved p53-target
ACCESSION NO.:NP_037531
PROTEIN GI NO.:118344450
OFFICIAL SYMBOL:CDIP1
GENE ID:29965

Background

BACKGROUND:CDIP Antibody: The p53 tumor-suppressor gene integrates numerous signals that control cell life and death; loss of its functions contributes to the development of most cancers. CDIP is a novel pro-apoptotic target gene whose inhibition abrogates p53-mediated apoptotic responses. Overexpression of CDIP induced apoptosis in transfected cells while siRNA suppression of caspase-8 mRNA blocked this CDIP-induced apoptosis, indicating that the CDIP-dependent apoptosis pathway proceeds through extrinsic cell death pathway. CDIP may thus represent a novel target for drug design to maximize p53 response and sensitize tumor cells to cancer therapy. Multiple isoforms of CDIP are known to exist.
REFERENCES: 1) Guimaraes DP and Hainaut P. TP53: a key gene in human cancer. Biochimie2002; 84:83-93.
2) Brown L, Ongusaha PP, Kim H-H, et al. CDIP, a novel pro-apoptotic gene, regulates TNFa-mediated apoptosis in a p53-dependent manner. EMBO J.2007; 26:3410-22.

For Research Use Only